KRSA (KRSA) FCF per Share: Latest Data, Historical Trends & Peer Comparison
What is KRSA's (KRSA) FCF per Share?
For the trailing twelve months (TTM) ended Dec 31, 2024, KRSA FCF per Share was -1.70, representing a +80.18% change year over year.
For fiscal Q4'24 ended Dec 31, 2024, KRSA FCF per Share was 0.14, representing a +122.7% change year over year.
For fiscal FY'24 ended Dec 31, 2024, KRSA FCF per Share was -1.70, representing a +80.18% change year over year.
FCF per Share Historical Trend for KRSA
View KRSA's annual, quarterly, and TTM FCF per Share data from 2019 to 2024, including historical growth rates and trend analysis.
KRSA TTM Data
| Metric | Q1'20Mar 31, 2020 | Q2'20Jun 30, 2020 | Q3'20Sep 30, 2020 | Q4'20Dec 31, 2020 | Q1'21Mar 31, 2021 | Q2'21Jun 30, 2021 | Q3'21Sep 30, 2021 | Q4'21Dec 31, 2021 | Q1'22Mar 31, 2022 | Q2'22Jun 30, 2022 | Q3'22Sep 30, 2022 | Q4'22Dec 31, 2022 | Q1'23Mar 31, 2023 | Q2'23Jun 30, 2023 | Q3'23Sep 30, 2023 | Q4'23Dec 31, 2023 | Q1'24Mar 31, 2024 | Q2'24Jun 30, 2024 | Q3'24Sep 30, 2024 | Q4'24Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF per Share YoY | -54.69 -- | -65.83 -- | -51.19 -- | -43.48 -- | -29.91 +45.31% | -20.48 +68.89% | -21.06 +58.86% | -16.83 +61.3% | -14.26 +52.3% | -18.48 +9.77% | -19.38 +7.97% | -18.66 -10.91% | -15.61 -9.44% | -13.09 +29.19% | -11.29 +41.77% | -8.59 +53.99% | -6.48 +58.49% | -4.47 +65.87% | -2.38 +78.89% | -1.70 +80.18% |
KRSA Quarterly Data
| Metric | Q1'19Mar 31, 2019 | Q2'19Jun 30, 2019 | Q3'19Sep 30, 2019 | Q4'19Dec 31, 2019 | Q1'20Mar 31, 2020 | Q2'20Jun 30, 2020 | Q3'20Sep 30, 2020 | Q4'20Dec 31, 2020 | Q1'21Mar 31, 2021 | Q2'21Jun 30, 2021 | Q3'21Sep 30, 2021 | Q4'21Dec 31, 2021 | Q1'22Mar 31, 2022 | Q2'22Jun 30, 2022 | Q3'22Sep 30, 2022 | Q4'22Dec 31, 2022 | Q1'23Mar 31, 2023 | Q2'23Jun 30, 2023 | Q3'23Sep 30, 2023 | Q4'23Dec 31, 2023 | Q1'24Mar 31, 2024 | Q2'24Jun 30, 2024 | Q3'24Sep 30, 2024 | Q4'24Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF per Share YoY | -46.42 -- | -19.13 -- | -17.81 -- | -16.19 -- | -22.04 +52.52% | -10.26 +46.34% | -8.87 +50.22% | -8.27 +48.92% | -8.47 +61.57% | -2.55 +75.19% | -3.66 +58.7% | -3.98 +51.91% | -5.91 +30.25% | -4.98 -95.45% | -4.56 -24.5% | -3.24 +18.59% | -2.86 +51.67% | -2.72 +45.29% | -2.84 +37.79% | -0.62 +80.76% | -0.75 +73.79% | -0.44 +83.85% | -0.68 +76.09% | 0.14 +122.7% |
KRSA Annual Data
| Metric | FY'19Dec 31, 2019 | FY'20Dec 31, 2020 | FY'21Dec 31, 2021 | FY'22Dec 31, 2022 | FY'23Dec 31, 2023 | FY'24Dec 31, 2024 |
|---|---|---|---|---|---|---|
FCF per Share YoY | -79.07 -- | -43.48 +45.01% | -16.83 +61.3% | -18.66 -10.91% | -8.59 +53.99% | -1.70 +80.18% |
KRSA (KRSA) : Definition & Explanation
FCF per Share takes a company-wide financial number and translates it into a per-share figure. That makes it easier for stock investors to connect business performance with what each share represents.
It matters because fcf per share is often closer to how the market prices a stock. It also makes dilution, buybacks, and shareholder economics easier to understand.
It is usually calculated by dividing a reported or adjusted company-wide figure by shares outstanding or weighted average diluted shares, depending on the metric.
Investors usually read fcf per share together with the total share count, issuance or buybacks, and valuation ratios. Per-share improvement is most meaningful when it is backed by real improvement in the business, not just a changing denominator.
KRSA (KRSA) FCF per Share vs Competitors | Chemical Pharmaceuticals Comparison
Compare KRSA's (KRSA) FCF per Share with competitors. View latest market cap and FCF per Share performance.
| Ticker | Company | Market Cap | FCF per Share |
|---|---|---|---|
| LLY | Eli Lilly | 1.08T | -- |
| JNJ | Johnson & Johnson | 651.20B | -- |
| ABBV | Abbvie | 466.55B | -- |
| NVS | Novartis | 267.85B | -- |
| NVO | Novo Nordisk | 190.81B | -- |
| BMY | Bristol-Myers Squibb | 128.36B | -- |
| SNY | Sanofi | 104.75B | -- |
| GSK | GSK | 103.28B | -- |
| TAK | Takeda Pharmaceutical | 60.21B | -- |
| TEVA | Teva Pharmaceutical | 45.71B | -- |
| ONC | Beone Medicines | 40.19B | -- |
| RPRX | Royalty Pharma | 33.88B | -- |
| VTRS | Viatris | 19.68B | -- |
| JAZZ | Jazz Pharmaceuticals | 15.83B | -- |
| NBIX | Neurocrine Biosciences | 15.43B | -- |
| EXEL | Exelixis | 14.49B | -- |
| CORT | Corcept Therapeutics | 12.42B | -- |
| MDGL | Madrigal | 12.35B | -- |
| AXSM | Axsome Therapeutics | 11.22B | -- |
| RDY | Dr. Reddy'S Laboratories | 10.17B | -- |
| ALKS | Alkermes | 7.84B | -- |
| BLTE | Belite Bio | 6.86B | -- |
| RYTM | Rhythm | 6.82B | -- |
| MIRM | Mirum | 6.42B | -- |
| BLCO | Bausch + Lomb | 5.99B | -- |
| AMRX | Amneal | 5.84B | -- |
| LGND | Ligand | 5.68B | -- |
| DFTX | Definium | 5.20B | -- |
| AMLX | Amylyx | 4.26B | -- |
| TLX | Telix | 4.25B | -0.13 |
KRSA (KRSA) FCF per Share Related Metrics
Explore key financial metrics related to KRSA's (KRSA) FCF per Share. Click on the links below to dive deeper into similar and complementary indicators.
About KRSA (KRSA)
KRSA
Industry
--
Established Date
--
Listing Date
--
Exchange
--
Full-time Employees
--
Fiscal Year Ends
--
Website
--
Security Type
--
Office address
--
Business
--
Introduction
--